Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

Currently, ERY974, a humanized IgG4 bispecific T cell-redirecting antibody recognizing glypican-3 and CD3, is in phase I clinical trials. After a first-in-human clinical trial of an anti-CD28 agonist monoclonal antibody resulting in severe life-threatening adverse events, the minimal anticipated bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Komatsu, Shun-ichiro, Kayukawa, Yoko, Miyazaki, Yoko, Kaneko, Akihisa, Ikegami, Hisashi, Ishiguro, Takahiro, Nakamura, Mikiko, Frings, Werner, Ono, Natsuki, Sakata, Kiyoaki, Fujii, Toshihiko, Kishishita, Shohei, Kitazawa, Takehisa, Endo, Mika, Sano, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296674/
https://www.ncbi.nlm.nih.gov/pubmed/35853994
http://dx.doi.org/10.1038/s41598-022-16564-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296674/
https://www.ncbi.nlm.nih.gov/pubmed/35853994
http://dx.doi.org/10.1038/s41598-022-16564-x

Ejemplares similares